FDA approves Ultragenyx gene therapy for glycogen storage disorder; Overton faces confirmation hurdles

The U.S. Food and Drug Administration has granted approval to Ultragenyx's gene therapy aimed at treating a glycogen storage disorder. This marks a regulatory milestone for the company and the rare disease community.

The therapy is designed to address the underlying genetic defect that leads to abnormal glycogen accumulation, offering a potential disease‑modifying option for patients.

Separately, Overton is encountering challenges in confirming certain aspects of its related development program, which could affect timelines and further regulatory steps.

The approval underscores ongoing progress in gene‑based treatments, while the confirmation issues highlight the complexities that can arise even after a product receives market clearance.